nodes	percent_of_prediction	percent_of_DWPC	metapath
Sucralfate—FGF2—hypertension	0.435	0.872	CbGaD
Sucralfate—ALB—hypertension	0.0639	0.128	CbGaD
Sucralfate—ALB—Ethacrynic acid—hypertension	0.0404	0.349	CbGbCtD
Sucralfate—ALB—Valsartan—hypertension	0.0261	0.225	CbGbCtD
Sucralfate—ALB—Captopril—hypertension	0.019	0.164	CbGbCtD
Sucralfate—ALB—Furosemide—hypertension	0.0153	0.132	CbGbCtD
Sucralfate—ALB—Losartan—hypertension	0.015	0.129	CbGbCtD
Sucralfate—EGF—nephron—hypertension	0.00769	0.103	CbGeAlD
Sucralfate—EGF—endothelium—hypertension	0.00362	0.0487	CbGeAlD
Sucralfate—PGA5—kidney—hypertension	0.00343	0.0462	CbGeAlD
Sucralfate—FGG—adrenal cortex—hypertension	0.00339	0.0455	CbGeAlD
Sucralfate—EGF—blood vessel—hypertension	0.00334	0.0449	CbGeAlD
Sucralfate—FGG—decidua—hypertension	0.00318	0.0428	CbGeAlD
Sucralfate—Haemolysis—Enalapril—hypertension	0.00263	0.0329	CcSEcCtD
Sucralfate—Venous thrombosis—Metolazone—hypertension	0.00259	0.0324	CcSEcCtD
Sucralfate—FGB—heart—hypertension	0.00253	0.034	CbGeAlD
Sucralfate—FGA—brainstem—hypertension	0.0025	0.0336	CbGeAlD
Sucralfate—FGG—adrenal gland—hypertension	0.00244	0.0329	CbGeAlD
Sucralfate—FGB—cardiovascular system—hypertension	0.00239	0.0321	CbGeAlD
Sucralfate—FGB—kidney—hypertension	0.00233	0.0314	CbGeAlD
Sucralfate—Haemolysis—Losartan—hypertension	0.0023	0.0287	CcSEcCtD
Sucralfate—PGA5—central nervous system—hypertension	0.00217	0.0292	CbGeAlD
Sucralfate—FGA—heart—hypertension	0.00216	0.0291	CbGeAlD
Sucralfate—FGA—decidua—hypertension	0.0021	0.0283	CbGeAlD
Sucralfate—FGA—cardiovascular system—hypertension	0.00204	0.0275	CbGeAlD
Sucralfate—FGA—kidney—hypertension	0.002	0.0269	CbGeAlD
Sucralfate—Fluid overload—Guanabenz—hypertension	0.00185	0.0231	CcSEcCtD
Sucralfate—EGF—brainstem—hypertension	0.00183	0.0246	CbGeAlD
Sucralfate—EGF—nephron tubule—hypertension	0.00166	0.0223	CbGeAlD
Sucralfate—FGB—endocrine gland—hypertension	0.00164	0.022	CbGeAlD
Sucralfate—Fluid overload—Carvedilol—hypertension	0.00163	0.0203	CcSEcCtD
Sucralfate—Lung disorder—Guanabenz—hypertension	0.00162	0.0203	CcSEcCtD
Sucralfate—EGF—heart—hypertension	0.00158	0.0212	CbGeAlD
Sucralfate—EGF—smooth muscle tissue—hypertension	0.00157	0.0211	CbGeAlD
Sucralfate—Extravasation—Esmolol—hypertension	0.00156	0.0195	CcSEcCtD
Sucralfate—EGF—cardiovascular system—hypertension	0.00149	0.0201	CbGeAlD
Sucralfate—EGF—kidney—hypertension	0.00146	0.0196	CbGeAlD
Sucralfate—Lung disorder—Indapamide—hypertension	0.00144	0.018	CcSEcCtD
Sucralfate—Lung disorder—Carvedilol—hypertension	0.00143	0.0179	CcSEcCtD
Sucralfate—EGF—cortex of kidney—hypertension	0.00142	0.0191	CbGeAlD
Sucralfate—FGA—endocrine gland—hypertension	0.0014	0.0188	CbGeAlD
Sucralfate—FGF2—heart—hypertension	0.00139	0.0187	CbGeAlD
Sucralfate—FGF2—smooth muscle tissue—hypertension	0.00138	0.0186	CbGeAlD
Sucralfate—FGF2—decidua—hypertension	0.00136	0.0182	CbGeAlD
Sucralfate—EGF—cardiac atrium—hypertension	0.00135	0.0182	CbGeAlD
Sucralfate—Hyponatraemia—Torasemide—hypertension	0.00132	0.0165	CcSEcCtD
Sucralfate—FGA—central nervous system—hypertension	0.00126	0.017	CbGeAlD
Sucralfate—Hyponatraemia—Chlorthalidone—hypertension	0.00126	0.0158	CcSEcCtD
Sucralfate—Hyponatraemia—Bumetanide—hypertension	0.00125	0.0157	CcSEcCtD
Sucralfate—EGF—adrenal gland—hypertension	0.00118	0.0159	CbGeAlD
Sucralfate—Lung disorder—Telmisartan—hypertension	0.00117	0.0146	CcSEcCtD
Sucralfate—Hyponatraemia—Candesartan—hypertension	0.00114	0.0143	CcSEcCtD
Sucralfate—FGF2—medulla oblongata—hypertension	0.00112	0.0151	CbGeAlD
Sucralfate—Hyponatraemia—Amiloride—hypertension	0.00111	0.0138	CcSEcCtD
Sucralfate—Hyponatraemia—Benazepril—hypertension	0.00106	0.0132	CcSEcCtD
Sucralfate—FGF2—adrenal gland—hypertension	0.00104	0.014	CbGeAlD
Sucralfate—EGF—endocrine gland—hypertension	0.00102	0.0138	CbGeAlD
Sucralfate—Hyponatraemia—Metolazone—hypertension	0.00102	0.0127	CcSEcCtD
Sucralfate—EGF—central nervous system—hypertension	0.000922	0.0124	CbGeAlD
Sucralfate—Hyponatraemia—Eprosartan—hypertension	0.000918	0.0115	CcSEcCtD
Sucralfate—Fluid overload—Lisinopril—hypertension	0.000914	0.0114	CcSEcCtD
Sucralfate—Phlebitis—Diltiazem—hypertension	0.000861	0.0108	CcSEcCtD
Sucralfate—Hyponatraemia—Guanabenz—hypertension	0.000838	0.0105	CcSEcCtD
Sucralfate—Phlebitis—Nifedipine—hypertension	0.000821	0.0103	CcSEcCtD
Sucralfate—Hyponatraemia—Indapamide—hypertension	0.000744	0.00931	CcSEcCtD
Sucralfate—Hyponatraemia—Carvedilol—hypertension	0.000737	0.00922	CcSEcCtD
Sucralfate—Oedema—Reserpine—hypertension	0.000729	0.00911	CcSEcCtD
Sucralfate—Hyponatraemia—Fosinopril—hypertension	0.00072	0.009	CcSEcCtD
Sucralfate—Hyponatraemia—Eplerenone—hypertension	0.000716	0.00895	CcSEcCtD
Sucralfate—Hyponatraemia—Valsartan—hypertension	0.000659	0.00824	CcSEcCtD
Sucralfate—Hyponatraemia—Olmesartan—hypertension	0.000655	0.0082	CcSEcCtD
Sucralfate—Oedema—Torasemide—hypertension	0.000646	0.00808	CcSEcCtD
Sucralfate—Oedema—Prazosin—hypertension	0.000614	0.00767	CcSEcCtD
Sucralfate—Hyponatraemia—Trandolapril—hypertension	0.000612	0.00766	CcSEcCtD
Sucralfate—Hyponatraemia—Enalapril—hypertension	0.00061	0.00763	CcSEcCtD
Sucralfate—Hyponatraemia—Captopril—hypertension	0.000585	0.00731	CcSEcCtD
Sucralfate—Oedema—Bepridil—hypertension	0.00058	0.00725	CcSEcCtD
Sucralfate—Body temperature increased—Ethacrynic acid—hypertension	0.000576	0.0072	CcSEcCtD
Sucralfate—Hyponatraemia—Perindopril—hypertension	0.000568	0.0071	CcSEcCtD
Sucralfate—Hyponatraemia—Irbesartan—hypertension	0.000566	0.00708	CcSEcCtD
Sucralfate—Hyponatraemia—Hydrochlorothiazide—hypertension	0.000561	0.00702	CcSEcCtD
Sucralfate—Body temperature increased—Fenoldopam—hypertension	0.000556	0.00695	CcSEcCtD
Sucralfate—Oedema—Methyldopa—hypertension	0.000552	0.0069	CcSEcCtD
Sucralfate—Hyponatraemia—Furosemide—hypertension	0.000552	0.0069	CcSEcCtD
Sucralfate—Infection—Methyldopa—hypertension	0.000549	0.00686	CcSEcCtD
Sucralfate—ALB—heart—hypertension	0.000546	0.00735	CbGeAlD
Sucralfate—Oedema—Hydralazine—hypertension	0.000542	0.00678	CcSEcCtD
Sucralfate—Oedema—Pindolol—hypertension	0.000535	0.00669	CcSEcCtD
Sucralfate—Hyponatraemia—Losartan—hypertension	0.000533	0.00666	CcSEcCtD
Sucralfate—Oedema—Quinapril—hypertension	0.000526	0.00658	CcSEcCtD
Sucralfate—Infection—Quinapril—hypertension	0.000523	0.00654	CcSEcCtD
Sucralfate—Oedema—Benazepril—hypertension	0.000518	0.00647	CcSEcCtD
Sucralfate—Oedema—Nadolol—hypertension	0.000516	0.00645	CcSEcCtD
Sucralfate—Infection—Benazepril—hypertension	0.000514	0.00643	CcSEcCtD
Sucralfate—Oedema—Isradipine—hypertension	0.000508	0.00635	CcSEcCtD
Sucralfate—Oedema—Guanfacine—hypertension	0.000506	0.00633	CcSEcCtD
Sucralfate—Oedema—Nicardipine—hypertension	0.000504	0.0063	CcSEcCtD
Sucralfate—Infection—Nicardipine—hypertension	0.000501	0.00626	CcSEcCtD
Sucralfate—Body temperature increased—Chlorothiazide—hypertension	0.000497	0.00622	CcSEcCtD
Sucralfate—Oedema—Esmolol—hypertension	0.000486	0.00608	CcSEcCtD
Sucralfate—Body temperature increased—Prazosin—hypertension	0.000485	0.00607	CcSEcCtD
Sucralfate—Oedema—Terazosin—hypertension	0.00048	0.006	CcSEcCtD
Sucralfate—Oedema—Acebutolol—hypertension	0.000468	0.00585	CcSEcCtD
Sucralfate—Oedema—Labetalol—hypertension	0.000464	0.0058	CcSEcCtD
Sucralfate—Body temperature increased—Bepridil—hypertension	0.000459	0.00573	CcSEcCtD
Sucralfate—Hyponatraemia—Ramipril—hypertension	0.000457	0.00571	CcSEcCtD
Sucralfate—Body temperature increased—Penbutolol—hypertension	0.000454	0.00567	CcSEcCtD
Sucralfate—Body temperature increased—Candesartan—hypertension	0.000443	0.00554	CcSEcCtD
Sucralfate—Body temperature increased—Methyldopa—hypertension	0.000436	0.00546	CcSEcCtD
Sucralfate—Oedema—Amlodipine—hypertension	0.000436	0.00545	CcSEcCtD
Sucralfate—Oedema—Nisoldipine—hypertension	0.000436	0.00545	CcSEcCtD
Sucralfate—Body temperature increased—Hydralazine—hypertension	0.000429	0.00536	CcSEcCtD
Sucralfate—Hyponatraemia—Lisinopril—hypertension	0.000414	0.00518	CcSEcCtD
Sucralfate—Oedema—Guanabenz—hypertension	0.00041	0.00513	CcSEcCtD
Sucralfate—Oedema—Metoprolol—hypertension	0.00041	0.00513	CcSEcCtD
Sucralfate—Body temperature increased—Nadolol—hypertension	0.000408	0.0051	CcSEcCtD
Sucralfate—ALB—adrenal gland—hypertension	0.000408	0.00548	CbGeAlD
Sucralfate—Infection—Guanabenz—hypertension	0.000407	0.00509	CcSEcCtD
Sucralfate—Body temperature increased—Nicardipine—hypertension	0.000398	0.00498	CcSEcCtD
Sucralfate—Body temperature increased—Felodipine—hypertension	0.000394	0.00493	CcSEcCtD
Sucralfate—Body temperature increased—Spironolactone—hypertension	0.000393	0.00491	CcSEcCtD
Sucralfate—Body temperature increased—Esmolol—hypertension	0.000385	0.00481	CcSEcCtD
Sucralfate—Body temperature increased—Terazosin—hypertension	0.000379	0.00474	CcSEcCtD
Sucralfate—Infection—Propranolol—hypertension	0.000374	0.00468	CcSEcCtD
Sucralfate—Body temperature increased—Acebutolol—hypertension	0.00037	0.00463	CcSEcCtD
Sucralfate—Body temperature increased—Labetalol—hypertension	0.000367	0.00458	CcSEcCtD
Sucralfate—Oedema—Indapamide—hypertension	0.000364	0.00456	CcSEcCtD
Sucralfate—Oedema—Diltiazem—hypertension	0.000364	0.00456	CcSEcCtD
Sucralfate—Infection—Diltiazem—hypertension	0.000362	0.00453	CcSEcCtD
Sucralfate—Infection—Indapamide—hypertension	0.000362	0.00453	CcSEcCtD
Sucralfate—Oedema—Carvedilol—hypertension	0.000361	0.00451	CcSEcCtD
Sucralfate—Infection—Carvedilol—hypertension	0.000359	0.00448	CcSEcCtD
Sucralfate—Oedema—Doxazosin—hypertension	0.000357	0.00446	CcSEcCtD
Sucralfate—Body temperature increased—Eprosartan—hypertension	0.000355	0.00444	CcSEcCtD
Sucralfate—Infection—Doxazosin—hypertension	0.000355	0.00443	CcSEcCtD
Sucralfate—Oedema—Fosinopril—hypertension	0.000353	0.00441	CcSEcCtD
Sucralfate—Infection—Fosinopril—hypertension	0.00035	0.00438	CcSEcCtD
Sucralfate—Infection—Eplerenone—hypertension	0.000348	0.00435	CcSEcCtD
Sucralfate—Oedema—Nifedipine—hypertension	0.000348	0.00435	CcSEcCtD
Sucralfate—Oedema—Verapamil—hypertension	0.000346	0.00433	CcSEcCtD
Sucralfate—Body temperature increased—Nisoldipine—hypertension	0.000345	0.00431	CcSEcCtD
Sucralfate—Infection—Verapamil—hypertension	0.000344	0.0043	CcSEcCtD
Sucralfate—Body temperature increased—Metoprolol—hypertension	0.000324	0.00405	CcSEcCtD
Sucralfate—Body temperature increased—Guanabenz—hypertension	0.000324	0.00405	CcSEcCtD
Sucralfate—Oedema—Valsartan—hypertension	0.000322	0.00403	CcSEcCtD
Sucralfate—Oedema—Olmesartan—hypertension	0.000321	0.00401	CcSEcCtD
Sucralfate—Infection—Valsartan—hypertension	0.00032	0.00401	CcSEcCtD
Sucralfate—Infection—Olmesartan—hypertension	0.000319	0.00399	CcSEcCtD
Sucralfate—Oedema—Clonidine—hypertension	0.000307	0.00384	CcSEcCtD
Sucralfate—Infection—Clonidine—hypertension	0.000305	0.00382	CcSEcCtD
Sucralfate—Oedema—Trandolapril—hypertension	0.0003	0.00375	CcSEcCtD
Sucralfate—Oedema—Enalapril—hypertension	0.000299	0.00373	CcSEcCtD
Sucralfate—Infection—Trandolapril—hypertension	0.000298	0.00372	CcSEcCtD
Sucralfate—Body temperature increased—Propranolol—hypertension	0.000298	0.00372	CcSEcCtD
Sucralfate—Oedema—Telmisartan—hypertension	0.000294	0.00368	CcSEcCtD
Sucralfate—Infection—Telmisartan—hypertension	0.000293	0.00366	CcSEcCtD
Sucralfate—Body temperature increased—Diltiazem—hypertension	0.000288	0.0036	CcSEcCtD
Sucralfate—Body temperature increased—Indapamide—hypertension	0.000288	0.0036	CcSEcCtD
Sucralfate—Body temperature increased—Carvedilol—hypertension	0.000285	0.00357	CcSEcCtD
Sucralfate—Body temperature increased—Doxazosin—hypertension	0.000282	0.00353	CcSEcCtD
Sucralfate—Body temperature increased—Fosinopril—hypertension	0.000279	0.00348	CcSEcCtD
Sucralfate—Oedema—Perindopril—hypertension	0.000278	0.00348	CcSEcCtD
Sucralfate—Oedema—Irbesartan—hypertension	0.000277	0.00346	CcSEcCtD
Sucralfate—Body temperature increased—Eplerenone—hypertension	0.000277	0.00346	CcSEcCtD
Sucralfate—Infection—Irbesartan—hypertension	0.000275	0.00344	CcSEcCtD
Sucralfate—Body temperature increased—Nifedipine—hypertension	0.000275	0.00344	CcSEcCtD
Sucralfate—Oedema—Hydrochlorothiazide—hypertension	0.000275	0.00344	CcSEcCtD
Sucralfate—Oedema—Betaxolol—hypertension	0.000268	0.00335	CcSEcCtD
Sucralfate—Infection—Betaxolol—hypertension	0.000266	0.00332	CcSEcCtD
Sucralfate—Oedema—Losartan—hypertension	0.000261	0.00326	CcSEcCtD
Sucralfate—Infection—Losartan—hypertension	0.000259	0.00324	CcSEcCtD
Sucralfate—Body temperature increased—Olmesartan—hypertension	0.000254	0.00317	CcSEcCtD
Sucralfate—Body temperature increased—Clonidine—hypertension	0.000243	0.00304	CcSEcCtD
Sucralfate—Body temperature increased—Trandolapril—hypertension	0.000237	0.00296	CcSEcCtD
Sucralfate—Body temperature increased—Enalapril—hypertension	0.000236	0.00295	CcSEcCtD
Sucralfate—Body temperature increased—Telmisartan—hypertension	0.000233	0.00291	CcSEcCtD
Sucralfate—Body temperature increased—Captopril—hypertension	0.000226	0.00283	CcSEcCtD
Sucralfate—Oedema—Ramipril—hypertension	0.000224	0.0028	CcSEcCtD
Sucralfate—Body temperature increased—Perindopril—hypertension	0.00022	0.00275	CcSEcCtD
Sucralfate—Body temperature increased—Irbesartan—hypertension	0.000219	0.00274	CcSEcCtD
Sucralfate—Oedema—Timolol—hypertension	0.000219	0.00273	CcSEcCtD
Sucralfate—Body temperature increased—Hydrochlorothiazide—hypertension	0.000217	0.00272	CcSEcCtD
Sucralfate—Infection—Timolol—hypertension	0.000217	0.00272	CcSEcCtD
Sucralfate—Body temperature increased—Furosemide—hypertension	0.000214	0.00267	CcSEcCtD
Sucralfate—Body temperature increased—Betaxolol—hypertension	0.000212	0.00264	CcSEcCtD
Sucralfate—Body temperature increased—Losartan—hypertension	0.000206	0.00258	CcSEcCtD
Sucralfate—Oedema—Lisinopril—hypertension	0.000203	0.00254	CcSEcCtD
Sucralfate—Infection—Lisinopril—hypertension	0.000201	0.00252	CcSEcCtD
Sucralfate—Body temperature increased—Ramipril—hypertension	0.000177	0.00221	CcSEcCtD
Sucralfate—Body temperature increased—Timolol—hypertension	0.000173	0.00216	CcSEcCtD
Sucralfate—Body temperature increased—Lisinopril—hypertension	0.00016	0.002	CcSEcCtD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—APOB—hypertension	2.8e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC2A3—hypertension	2.79e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALAS1—hypertension	2.79e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP11B2—hypertension	2.79e-06	1.21e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCL5—hypertension	2.79e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—GNB3—hypertension	2.79e-06	1.21e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—INS—hypertension	2.79e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CD36—hypertension	2.79e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—HMOX1—hypertension	2.78e-06	1.2e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HSD3B1—hypertension	2.75e-06	1.19e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ADA—hypertension	2.75e-06	1.19e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—AVP—hypertension	2.75e-06	1.19e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—FGF2—hypertension	2.74e-06	1.19e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—RHOA—hypertension	2.73e-06	1.18e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—LPL—hypertension	2.73e-06	1.18e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—GNAS—hypertension	2.71e-06	1.18e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—EGFR—hypertension	2.71e-06	1.18e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—FADS1—hypertension	2.71e-06	1.18e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—AQP1—hypertension	2.71e-06	1.18e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—H2AFX—hypertension	2.71e-06	1.17e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3R1—hypertension	2.71e-06	1.17e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—NOS3—hypertension	2.71e-06	1.17e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PDGFRB—hypertension	2.7e-06	1.17e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RPS6KB1—hypertension	2.7e-06	1.17e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PRKCD—hypertension	2.7e-06	1.17e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—AKT2—hypertension	2.69e-06	1.17e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—LPL—hypertension	2.67e-06	1.16e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ADCY5—hypertension	2.67e-06	1.16e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—APOB—hypertension	2.66e-06	1.15e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PRKCG—hypertension	2.65e-06	1.15e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3R1—hypertension	2.65e-06	1.15e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—SRC—hypertension	2.64e-06	1.15e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CA9—hypertension	2.64e-06	1.14e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—TBXAS1—hypertension	2.64e-06	1.14e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ITGB3—hypertension	2.63e-06	1.14e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PRKCA—hypertension	2.63e-06	1.14e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—YWHAZ—hypertension	2.61e-06	1.13e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—GPX1—hypertension	2.6e-06	1.13e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SPP1—hypertension	2.58e-06	1.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NGF—hypertension	2.58e-06	1.12e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CYP1A1—hypertension	2.58e-06	1.12e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—VEGFA—hypertension	2.57e-06	1.12e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALOX5AP—hypertension	2.57e-06	1.11e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALOX15—hypertension	2.57e-06	1.11e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PDGFB—hypertension	2.57e-06	1.11e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—IL6—hypertension	2.57e-06	1.11e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—SERPINE1—hypertension	2.56e-06	1.11e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—MYC—hypertension	2.56e-06	1.11e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—TGFB1—hypertension	2.55e-06	1.11e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—BCL2—hypertension	2.55e-06	1.1e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—RELA—hypertension	2.55e-06	1.1e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—MMP1—hypertension	2.54e-06	1.1e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CD36—hypertension	2.54e-06	1.1e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PRKCD—hypertension	2.51e-06	1.09e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCR5—hypertension	2.51e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—LHB—hypertension	2.51e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HADHA—hypertension	2.51e-06	1.09e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—EGFR—hypertension	2.5e-06	1.09e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MTOR—hypertension	2.5e-06	1.08e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—RELA—hypertension	2.49e-06	1.08e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—ADCY5—hypertension	2.49e-06	1.08e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—RHOA—hypertension	2.47e-06	1.07e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CALM1—hypertension	2.47e-06	1.07e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HTR2A—hypertension	2.46e-06	1.07e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—C3—hypertension	2.45e-06	1.06e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—LPA—hypertension	2.45e-06	1.06e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—KCNJ11—hypertension	2.45e-06	1.06e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HSD3B2—hypertension	2.45e-06	1.06e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3R1—hypertension	2.44e-06	1.06e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—NOS3—hypertension	2.44e-06	1.06e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MTOR—hypertension	2.44e-06	1.06e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CAV1—hypertension	2.44e-06	1.06e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—APOA1—hypertension	2.43e-06	1.05e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—TP53—hypertension	2.41e-06	1.04e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CXCL8—hypertension	2.4e-06	1.04e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PDGFB—hypertension	2.39e-06	1.04e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FGFR1—hypertension	2.38e-06	1.03e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—AKT1—hypertension	2.37e-06	1.03e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—TGFB1—hypertension	2.36e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—TP53—hypertension	2.36e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—TP53—hypertension	2.36e-06	1.02e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PPARA—hypertension	2.36e-06	1.02e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—LRP2—hypertension	2.35e-06	1.02e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP2C18—hypertension	2.35e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HIF1A—hypertension	2.34e-06	1.01e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—AGT—hypertension	2.33e-06	1.01e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—F2—hypertension	2.32e-06	1e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PRKCB—hypertension	2.32e-06	1e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—FN1—hypertension	2.32e-06	1e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CALM1—hypertension	2.29e-06	9.94e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—NOS2—hypertension	2.29e-06	9.93e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—LEP—hypertension	2.29e-06	9.9e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—APOE—hypertension	2.29e-06	9.9e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—AGT—hypertension	2.28e-06	9.9e-06	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—IL6—hypertension	2.27e-06	9.82e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CAV1—hypertension	2.26e-06	9.81e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HSPG2—hypertension	2.26e-06	9.81e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—APOA1—hypertension	2.26e-06	9.79e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—MTOR—hypertension	2.26e-06	9.78e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL1B—hypertension	2.25e-06	9.76e-06	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—PPARA—hypertension	2.24e-06	9.72e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KDR—hypertension	2.24e-06	9.7e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—APOE—hypertension	2.24e-06	9.7e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTGS2—hypertension	2.24e-06	9.69e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CAV1—hypertension	2.22e-06	9.61e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—APOA1—hypertension	2.21e-06	9.59e-06	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—IL6—hypertension	2.2e-06	9.55e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALOX5—hypertension	2.19e-06	9.47e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GLP1R—hypertension	2.19e-06	9.47e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MMP9—hypertension	2.17e-06	9.41e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CDKN1A—hypertension	2.16e-06	9.37e-06	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—IL6—hypertension	2.16e-06	9.36e-06	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—IL6—hypertension	2.16e-06	9.36e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PTEN—hypertension	2.16e-06	9.35e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FN1—hypertension	2.16e-06	9.34e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PRKCB—hypertension	2.16e-06	9.34e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—F2—hypertension	2.16e-06	9.34e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDKN1A—hypertension	2.12e-06	9.17e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PTEN—hypertension	2.11e-06	9.15e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MAPK8—hypertension	2.11e-06	9.15e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NOTCH1—hypertension	2.11e-06	9.14e-06	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—APOA1—hypertension	2.1e-06	9.11e-06	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—AKT1—hypertension	2.09e-06	9.06e-06	CbGpPWpGaD
Sucralfate—EGF—Immune System—IL6—hypertension	2.08e-06	9.03e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MAPK8—hypertension	2.07e-06	8.95e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EP300—hypertension	2.06e-06	8.92e-06	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—AKT1—hypertension	2.03e-06	8.81e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IGF1—hypertension	2.03e-06	8.8e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—AKT2—hypertension	2.03e-06	8.79e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EP300—hypertension	2.01e-06	8.73e-06	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—AKT1—hypertension	2.01e-06	8.7e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—SRC—hypertension	2e-06	8.67e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALDH2—hypertension	2e-06	8.66e-06	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—AKT1—hypertension	1.99e-06	8.63e-06	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—AKT1—hypertension	1.99e-06	8.63e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—POMC—hypertension	1.96e-06	8.51e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—SRC—hypertension	1.96e-06	8.49e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—CDKN1A—hypertension	1.95e-06	8.47e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—INS—hypertension	1.95e-06	8.46e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTEN—hypertension	1.95e-06	8.45e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PPARG—hypertension	1.95e-06	8.45e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—VEGFA—hypertension	1.95e-06	8.45e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HBA1—hypertension	1.95e-06	8.44e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP11A1—hypertension	1.94e-06	8.39e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—SERPINE1—hypertension	1.93e-06	8.36e-06	CbGpPWpGaD
Sucralfate—EGF—Disease—IL6—hypertension	1.92e-06	8.34e-06	CbGpPWpGaD
Sucralfate—EGF—Immune System—AKT1—hypertension	1.92e-06	8.33e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—POMC—hypertension	1.92e-06	8.33e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCL2—hypertension	1.92e-06	8.32e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTT1—hypertension	1.9e-06	8.24e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC9A1—hypertension	1.9e-06	8.24e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IGF1—hypertension	1.89e-06	8.18e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—AKT2—hypertension	1.89e-06	8.18e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GCLC—hypertension	1.88e-06	8.14e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CETP—hypertension	1.88e-06	8.14e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—RHOA—hypertension	1.86e-06	8.06e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—EP300—hypertension	1.86e-06	8.06e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—NOS3—hypertension	1.84e-06	7.98e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3R1—hypertension	1.84e-06	7.98e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—SRC—hypertension	1.81e-06	7.84e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP17A1—hypertension	1.8e-06	7.8e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SERPINE1—hypertension	1.79e-06	7.77e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MYC—hypertension	1.79e-06	7.77e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TGFB1—hypertension	1.79e-06	7.75e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ENO1—hypertension	1.78e-06	7.72e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTGS1—hypertension	1.78e-06	7.72e-06	CbGpPWpGaD
Sucralfate—EGF—Disease—AKT1—hypertension	1.78e-06	7.7e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EGFR—hypertension	1.75e-06	7.6e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RHOA—hypertension	1.73e-06	7.5e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EGFR—hypertension	1.72e-06	7.44e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CTGF—hypertension	1.72e-06	7.43e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3R1—hypertension	1.71e-06	7.42e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NOS3—hypertension	1.71e-06	7.42e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GOT2—hypertension	1.7e-06	7.37e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HMGCR—hypertension	1.7e-06	7.37e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hypertension	1.68e-06	7.26e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ADRA2A—hypertension	1.66e-06	7.21e-06	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—AKT1—hypertension	1.64e-06	7.12e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—MYC—hypertension	1.62e-06	7.02e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—TGFB1—hypertension	1.62e-06	7.01e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RELA—hypertension	1.61e-06	6.98e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—EGFR—hypertension	1.59e-06	6.87e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MTOR—hypertension	1.58e-06	6.85e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—TH—hypertension	1.56e-06	6.75e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CALM2—hypertension	1.55e-06	6.73e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTGS2—hypertension	1.53e-06	6.64e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CXCL8—hypertension	1.52e-06	6.58e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GCG—hypertension	1.52e-06	6.57e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC2A4—hypertension	1.52e-06	6.57e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TP53—hypertension	1.47e-06	6.38e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GOT1—hypertension	1.47e-06	6.36e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP19A1—hypertension	1.42e-06	6.17e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—STK11—hypertension	1.42e-06	6.17e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—EP300—hypertension	1.4e-06	6.07e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MMP9—hypertension	1.37e-06	5.95e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CDKN1A—hypertension	1.37e-06	5.93e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PTEN—hypertension	1.37e-06	5.92e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—SRC—hypertension	1.36e-06	5.9e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL6—hypertension	1.35e-06	5.84e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTEN—hypertension	1.34e-06	5.79e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAPK8—hypertension	1.34e-06	5.79e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—VEGFA—hypertension	1.33e-06	5.75e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—COMT—hypertension	1.32e-06	5.74e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL6—hypertension	1.32e-06	5.72e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PPARGC1A—hypertension	1.31e-06	5.66e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GNB3—hypertension	1.31e-06	5.66e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EP300—hypertension	1.3e-06	5.64e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HMOX1—hypertension	1.3e-06	5.63e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CAT—hypertension	1.28e-06	5.56e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—EP300—hypertension	1.28e-06	5.53e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GNAS—hypertension	1.27e-06	5.51e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SRC—hypertension	1.27e-06	5.49e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—APOB—hypertension	1.25e-06	5.4e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—AKT1—hypertension	1.24e-06	5.39e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—VEGFA—hypertension	1.23e-06	5.34e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—IL6—hypertension	1.22e-06	5.28e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TGFB1—hypertension	1.22e-06	5.28e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—AKT1—hypertension	1.22e-06	5.27e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTM1—hypertension	1.21e-06	5.25e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—LPL—hypertension	1.19e-06	5.15e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ADCY5—hypertension	1.16e-06	5.04e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GPX1—hypertension	1.16e-06	5.03e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PRKCA—hypertension	1.15e-06	4.98e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP1A1—hypertension	1.15e-06	4.98e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MYC—hypertension	1.13e-06	4.92e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TGFB1—hypertension	1.13e-06	4.91e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CD36—hypertension	1.13e-06	4.89e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—AKT1—hypertension	1.12e-06	4.87e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EGFR—hypertension	1.11e-06	4.81e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—MTHFR—hypertension	1.07e-06	4.64e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PPARA—hypertension	1.05e-06	4.55e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—AGT—hypertension	1.02e-06	4.41e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TP53—hypertension	1e-06	4.34e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CALM1—hypertension	1e-06	4.33e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—APOE—hypertension	9.97e-07	4.32e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CAV1—hypertension	9.87e-07	4.28e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—APOA1—hypertension	9.85e-07	4.27e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TP53—hypertension	9.32e-07	4.04e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PPARG—hypertension	8.68e-07	3.76e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—POMC—hypertension	8.56e-07	3.71e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL6—hypertension	8.53e-07	3.7e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—INS—hypertension	8.51e-07	3.69e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—AKT1—hypertension	8.46e-07	3.67e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—AKT1—hypertension	7.87e-07	3.41e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NOS3—hypertension	7.47e-07	3.24e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3R1—hypertension	7.47e-07	3.24e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTGS2—hypertension	6.83e-07	2.96e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTEN—hypertension	5.96e-07	2.58e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—EP300—hypertension	5.68e-07	2.46e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—AKT1—hypertension	3.43e-07	1.49e-06	CbGpPWpGaD
